FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046894249> ?p ?o ?g. }

• W3046894249 endingPage "1627" @default.
• W3046894249 startingPage "1623" @default.
• W3046894249 abstract "IL-1 induces a significant number of metabolic and hematological changes. In experimental animals, IL-1 treatments cause hypotension due to rapid reduction of systemic blood pressure, reduced vascular resistance, increased heart rate and leukocyte aggregations. IL-1 causes endothelial dysfunction, the triggering factor of which may be of a different nature including pathogen infection. This dysfunction, which includes macrophage intervention and increased protein permeability, can be mediated by several factors including cytokines and arachidonic acid products. These effects are caused by the induction of IL-1 in various pathologies, including those caused by pathogenic viral infections, including SARS-CoV-2 which provokes COVID-19. Activation of macrophages by coronavirus-19 leads to the release of pro-inflammatory cytokines, metalloproteinases and other proteolytic enzymes that can cause thrombi formation and severe respiratory dysfunction. Patients with COVID-19, seriously ill and hospitalized in intensive care, present systemic inflammation, intravascular coagulopathy with high risk of thrombotic complications, and venous thromboembolism, effects mostly mediated by IL-1. In these patients the lungs are the most critical target organ as it can present an increase in the degradation products of fibrin, fibrinogen and D-dimer, with organ lesions and respiratory failure. It is well known that IL-1 induces itself and another very important pro-inflammatory cytokine, TNF, which also participates in hemodynamic states, including shock syndrome in COVID-19. Both IL-1 and TNF cause pulmonary edema, thrombosis and bleeding. In addition to hypotension and resistance of systemic blood pressure, IL-1 causes leukopenia and thrombocytopenia. The formation of thrombi is the main complication of the circulatory system and functionality of the organ, and represents an important cause of morbidity and mortality. IL-1 causes platelet vascular thrombogenicity also on non-endothelial cells by stimulating the formation of thromboxane A2 which is released into the inflamed environment. IL-1 is the most important immune molecule in inducing fever, since it is involved in the metabolism of arachidonic acid which increases from vascular endothelial organs of the hypothalamus. The pathogenesis of thrombosis, vascular inflammation and angigenesis involves the mediation of the activation of the prostanoid thromboxane A2 receptor. In 1986, in an interesting article (Conti P, Reale M, Fiore S, Cancelli A, Angeletti PU, Dinarello CA. In vitro enhanced thromboxane B2 release by polymorphonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1. Prostaglandins. 1986 Jul;32(1):111-5), we reported for the first time that IL-1 induces thromboxane B2 (TxB2) releases in activated neutrophils and macrophages. An increase in thromboxane can induce leukocyte aggregation and systemic inflammation, which would account for the dramatic thrombi formation and organ dysfunction. Hence, IL-1 stimulates endothelial cell-leukocyte adhesion, and TxB2 production. All these events are supported by the large increase in neutrophils that adhere to the lung and the decrease in lymphocytes. Therefore, ecosanoids such as TxA2 (detected as TxB2) have a powerful action on vascular inflammation and platelet aggregation, mediating the formation of thrombi. The thrombogenesis that occurs in COVID-19 includes platelet and cell aggregation with clotting abnormalities, and anti-clotting inhibitor agents are used in the prevention and therapy of thrombotic diseases. Prevention of or induction of TxA2 avoids thrombi formation induced by IL-1. However, in some serious vascular events where TxA2 increases significantly, it is difficult to inhibit, therefore, it would be much better to prevent its induction and generation by blocking its inductors including IL-1. The inhibition or lack of formation of IL-1 avoids all the above pathological events which can lead to death of the patient. The treatment of innate immune cells producing IL-1 with IL-1 receptor antagonist (IL-1Ra) can avoid hemodynamic changes, septic shock and organ inflammation by carrying out a new therapeutic efficacy on COVID-19 induced by SARS-CoV-2." @default.
• W3046894249 created "2020-08-07" @default.
• W3046894249 creator A5018983637 @default.
• W3046894249 creator A5021355853 @default.
• W3046894249 creator A5037524218 @default.
• W3046894249 creator A5049034210 @default.
• W3046894249 creator A5054106836 @default.
• W3046894249 creator A5068152459 @default.
• W3046894249 creator A5071941913 @default.
• W3046894249 creator A5077573350 @default.
• W3046894249 creator A5086971584 @default.
• W3046894249 creator A5087329343 @default.
• W3046894249 date "2020-09-01" @default.
• W3046894249 modified "2023-10-06" @default.
• W3046894249 title "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)" @default.
• W3046894249 doi "https://doi.org/10.23812/20-34-4edit-65" @default.
• W3046894249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32744052" @default.
• W3046894249 hasPublicationYear "2020" @default.
• W3046894249 type Work @default.
• W3046894249 sameAs 3046894249 @default.
• W3046894249 citedByCount "35" @default.
• W3046894249 countsByYear W30468942492020 @default.
• W3046894249 countsByYear W30468942492021 @default.
• W3046894249 countsByYear W30468942492022 @default.
• W3046894249 countsByYear W30468942492023 @default.
• W3046894249 crossrefType "journal-article" @default.
• W3046894249 hasAuthorship W3046894249A5018983637 @default.
• W3046894249 hasAuthorship W3046894249A5021355853 @default.
• W3046894249 hasAuthorship W3046894249A5037524218 @default.
• W3046894249 hasAuthorship W3046894249A5049034210 @default.
• W3046894249 hasAuthorship W3046894249A5054106836 @default.
• W3046894249 hasAuthorship W3046894249A5068152459 @default.
• W3046894249 hasAuthorship W3046894249A5071941913 @default.
• W3046894249 hasAuthorship W3046894249A5077573350 @default.
• W3046894249 hasAuthorship W3046894249A5086971584 @default.
• W3046894249 hasAuthorship W3046894249A5087329343 @default.
• W3046894249 hasConcept C126322002 @default.
• W3046894249 hasConcept C203014093 @default.
• W3046894249 hasConcept C2776252253 @default.
• W3046894249 hasConcept C2776914184 @default.
• W3046894249 hasConcept C2778384902 @default.
• W3046894249 hasConcept C2778426790 @default.
• W3046894249 hasConcept C2779036427 @default.
• W3046894249 hasConcept C2780835948 @default.
• W3046894249 hasConcept C2780972559 @default.
• W3046894249 hasConcept C2781090800 @default.
• W3046894249 hasConcept C71924100 @default.
• W3046894249 hasConceptScore W3046894249C126322002 @default.
• W3046894249 hasConceptScore W3046894249C203014093 @default.
• W3046894249 hasConceptScore W3046894249C2776252253 @default.
• W3046894249 hasConceptScore W3046894249C2776914184 @default.
• W3046894249 hasConceptScore W3046894249C2778384902 @default.
• W3046894249 hasConceptScore W3046894249C2778426790 @default.
• W3046894249 hasConceptScore W3046894249C2779036427 @default.
• W3046894249 hasConceptScore W3046894249C2780835948 @default.
• W3046894249 hasConceptScore W3046894249C2780972559 @default.
• W3046894249 hasConceptScore W3046894249C2781090800 @default.
• W3046894249 hasConceptScore W3046894249C71924100 @default.
• W3046894249 hasIssue "5" @default.
• W3046894249 hasLocation W30468942491 @default.
• W3046894249 hasOpenAccess W3046894249 @default.
• W3046894249 hasPrimaryLocation W30468942491 @default.
• W3046894249 hasRelatedWork W1819052192 @default.
• W3046894249 hasRelatedWork W1982082531 @default.
• W3046894249 hasRelatedWork W1999438537 @default.
• W3046894249 hasRelatedWork W2173021033 @default.
• W3046894249 hasRelatedWork W2322629902 @default.
• W3046894249 hasRelatedWork W2396425622 @default.
• W3046894249 hasRelatedWork W2416852417 @default.
• W3046894249 hasRelatedWork W2441442485 @default.
• W3046894249 hasRelatedWork W2593340154 @default.
• W3046894249 hasRelatedWork W2936366881 @default.
• W3046894249 hasRelatedWork W3001118548 @default.
• W3046894249 hasRelatedWork W3009912996 @default.
• W3046894249 hasRelatedWork W3009914955 @default.
• W3046894249 hasRelatedWork W3012405893 @default.
• W3046894249 hasRelatedWork W3012421327 @default.
• W3046894249 hasRelatedWork W3014002534 @default.
• W3046894249 hasRelatedWork W3015863623 @default.
• W3046894249 hasRelatedWork W3130108111 @default.
• W3046894249 hasRelatedWork W345127876 @default.
• W3046894249 hasRelatedWork W799916511 @default.
• W3046894249 hasVolume "34" @default.
• W3046894249 isParatext "false" @default.
• W3046894249 isRetracted "false" @default.
• W3046894249 magId "3046894249" @default.
• W3046894249 workType "article" @default.